U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07114627) titled 'Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients' on Aug. 04.
Brief Summary: In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form. In the body, capecitabine is converted into the active molecule that has anti-cancer effects. This molecule is called 5-FU. The transformation of capecitabine to 5-FU occurs through specific proteins in the liver, also known as enzymes.
Unfortunately, capecitabine can also cause side effects. One of the most common side effects is hand-foot syndrome. In hand-foot syndrome, ...